NewswireToday - /newswire/ -
San Jose, CA, United States, 2009/06/23 - AnaSpec has announced the release of a new long wavelength assay for Lysine-Specific Demethylase –1 (LSD1), the SensoLyte® LSD1 Assay Kit, Ex/Em=530/590 nm.
LSD1 is a histone-modifying enzyme catalyzing lysine demethylation of histone H3. It plays an important role in regulation of gene expression, acting either as a transcription co-repressor or co-activator.1 The enzyme is implicated in cellular differentiation and has been considered as a potential target for drug discovery.2
The SensoLyteÒ LSD1 assay kit provides a convenient assay for screening of LSD1 inhibitors and for detection of LSD1 activity. This assay consists of two steps. In the first step, LSD1 enzyme is incubated with a methylated peptide substrate and hydrogen peroxide (H2O2) is generated. In the second step, in the presence of peroxidase, H2O2 reacts with fluorogenic substrate to produce fluorescence signal, which is monitored at Ex/Em=530/590 nm.
1. Culhane, J. C. et al. Curr Opin Chem Biol. 11, 561 (2007).
2. Shi, Y. Nat. Rev. Genet. 8, 829 (2007).
AnaSpec, Inc. (anaspec.com) is a leading provider of integrated proteomics solutions™ for worldwide life science research. With a vision for innovation through synergy, AnaSpec offers expertise in three primary technologies: peptides, detection reagents, and combinatorial chemistry. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. In conjunction, AnaSpec provides premier custom services including peptide synthesis, antibody production, and assay development. AnaSpec holds a California Drug Manufacturing License (License #41747) and a FDA Registration for GMP Drug Manufacturing (Registration #2951078).